Novo Nordisk's Guidance and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, will have continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback